Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 11, 2021 07:30 ET | Source: Monopar Therapeutics Inc. Monopar Therapeutics Inc. Wilmette, Illinois, UNITED STATES
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study in the
European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer.
Using Monopar’s proprietary humanized uPAR antibody, MNPR-101, a multimodal imaging probe was developed and tested